|
|
Incidence of Outcomes Per 1,000 Women
|
Tamoxifen
|
Raloxifene
|
RR, 95% CI
|
CI = confidence interval; RR = relative risk; VTE = venous thromboembolism.
|
Invasive breast cancer |
4.3 |
4.41 |
1.02, 0.82–1.28 |
Noninvasive breast cancer |
1.51 |
2.11 |
1.4, 0.98–2.00 |
Uterine cancer |
2.0 |
1.25 |
0.62, 0.35–1.08 |
VTE |
3.8 |
2.6 |
0.7, 0.68–0.99 |
Cataracts |
12.3 |
9.72 |
0.79, 0.68–0.92 |
Incidence of Symptoms (0–4 scale)
|
Favor Tamoxifen |
Dyspareunia |
0.68 |
0.78 |
P < .001 |
Musculoskeletal problems |
1.10 |
1.15 |
P = .002 |
Weight gain |
0.76 |
0.82 |
P < .001 |
Favor Raloxifene |
Vasomotor symptoms |
0.96 |
0.85 |
P < .001 |
Bladder control symptoms |
0.88 |
0.73 |
P < .001 |
Leg cramps |
1.10 |
0.91 |
P < .001 |
Gynecologic problems |
0.29 |
0.19 |
P < .001 |
|
|
|